Alfasigma Denmark ApS: Financial statements 2022
CVR: 42447242
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Alfasigma Denmark ApS (CVR 42447242) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 13,808,766 and a net result of DKK 1,445,936. Equity in the 2022 report amounted to DKK 1,884,187. The solvency ratio was 11.1%. The company had 6 employees in the financial year.
- Gross Profit
- DKK 13,808,766
- Profit/Loss
- DKK 1,445,936
- Equity
- DKK 1,884,187
- Total Assets
- DKK 17,048,597
- Employees
- 6
Official annual report
Keep an eye on Alfasigma Denmark ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Alfasigma Denmark ApS has published its interim report for the period June 3, 2021 – December 31, 2021.
About Alfasigma Denmark ApS
Alfasigma Denmark ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2021. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Galapagos Biopharma Denmark ApS. The management consists of Alberto Avaltroni, Alessio Battaglia and Line de Linde Henriksen. The company is owned by ALFASIGMA SpA. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 10,680,660 and a net result of DKK 505,448 compared with DKK 815,009 the year before. Equity in the 2025 report amounted to DKK 4,594,228.